Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Nearly 30 years of experience in the Korean/Asian equity research. Major sectors coverage include the following:
- Technology 
- Consumer 
- Special Situations/Deep Value Plays
- Tender Offers/M&As
- Holdcos/Stubs
- Asian Unicorns/Private Companies

Korea/Asia, Events, IPOs

Eoflow: Ozempic and Wegovy Reducing Need for Disposable Insulin Injection Devices + Ongoing Lawsuit?

Medtronic's M&A of Eoflow Timeline Postponed

Medtronic's M&A, Tender Offer, and Taking Private of Eoflow

Insulet's Lawsuit Against Eoflow, Medtronic's Tender Offer, and Eoflow's "Special Sauce"

An Update on Medtronic's Tender Offer of Eoflow

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Event-Driven

<ul>
<li>Eoflow (294090 KS)'s shares rose 2.7% to 27,000 won on 18 August with 1.4 million shares traded, which was 5.7x higher than the previous three days of trading.</li>
<li>The main reason for this was due to the local news flow on Eoflow's US subsidiary's (Nephria Bio) technology on the advanced material MXene.</li>
<li>This news flow on MXene is likely to put further positive boost to Eoflow's share price closer to the tender offer price (or at least limit further downside risk). </li>
</ul>


Eoflow (294090 KS)'s shares rose 2.7% to 27,000 won on 18 August with 1.4 million shares traded, which was 5.7x higher than the previous three days of trading.
The main reason for this was due to the local news flow on Eoflow's US subsidiary's (Nephria Bio) technology on the advanced material MXene.
This news flow on MXene is likely to put further positive boost to Eoflow's share price closer to the tender offer price (or at least limit further downside risk). 


Eoflow's US Subsidiary (Nephria Bio)'s Technology in MXene Advanced Material